IO Biotech Q3: Phase 3 melanoma trial narrowly misses PFS endpoint; cash $30.7M, runway to Q1 2026

IO Biotech, Inc.

2025-Q3 EPS reported -$0.86

Phase 3 IOB-013 trial in advanced melanoma showed PFS improvement but narrowly missed statistical significance; FDA meeting in December for new registrational trial design.
Q3 total operating expenses $19.4M, down from $26.5M YoY; R&D expenses $13.7M vs $20.2M prior year.
Cash and equivalents $30.7M as of Sep 30, 2025, down from $60.0M at Dec 31, 2024; expects to fund operations through Q1 2026.
Cash increased $2.5M in Q3 from €12.5M EIB loan drawdown and $6.6M net ATM proceeds.
Pre-clinical data for pipeline candidates IO112 (arginase 1) and IO170 (TGF-β) presented at SITC.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-281657
form_type: 8-K
ticker: IOBTQ
cik: 0001865494
company_name: IO Biotech, Inc.
filed_at: 2025-11-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.876580+00:00
generated_at: 2026-05-16T19:55:48.421207+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-281657
json_url: https://secwatch.observer/filing/0001193125-25-281657.json
markdown_url: https://secwatch.observer/filing/0001193125-25-281657.md
text_url: https://secwatch.observer/filing/0001193125-25-281657.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312525281657/0001193125-25-281657-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312525281657/d36523d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-281657

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.